The developability classification system (DCS) was proposed as a modification of the BCS to assist in the formulation of poorly soluble compounds. The DCS introduced two new compound categories: dissolution limited (DCS IIa) and solubility limited (DCS IIb). For DCS IIa molecules, particle size reduction and wetting agents can be considered. For DCS IIb compounds, solid-state modification can be utilized. Tune in to our webinar on the developability classification system to learn more about this emerging field of research, which allows more targeted and optimized formulation development of poorly soluble compounds.
Speaker
Daniel Joseph Price, Ph.D.
Merck
Strategic Marketing Manager
Daniel Joseph Price is a strategic marketing manager for our portfolio of solubility enhancement excipients. Prior to his current role, Daniel was a Marie Curie Fellow, conducting research on solubility enhancement with amorphous formulations. Daniel is an active member of several academia/industrial consortia on the topics of innovation in oral solid dosage forms and has published extensively on the topic in peer-reviewed journals. Daniel has a B.S. and an M.S. in chemistry from the University of Leeds and a Ph.D. in pharmaceutical technology from Frankfurt Goethe University.
Pharma and biopharma manufacturing
- Solid Formulation Strategies
Duration:1h
語言:English
會話 1:提出 November 2, 2021
若要繼續閱讀，請登入或建立帳戶。
還沒有帳戶？